tiprankstipranks
Gain Therapeutics, Inc. (GANX)
NASDAQ:GANX
US Market
GANX
Gain Therapeutics
RESEARCH TOOLSreports
Want to see GANX full AI Analyst Report?

Gain Therapeutics (GANX) Stock News & Sentiment

436 Followers
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
Premium
Ratings
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
1M ago
GANX
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
Premium
Company Announcements
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
2M ago
8K
GANX
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
2M ago
GANX
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
Premium
Ratings
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
4M ago
GANX
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
Premium
Ratings
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
4M ago
GANX
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
Premium
Ratings
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
4M ago
GANX
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
Premium
Ratings
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
4M ago
GANX
More GANX News >

GANX News on the Web

Gain Therapeutics management to meet with Maxim
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX)
TipRanks News
Bullish
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
TipRanks News
Bullish
Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON)
TipRanks News
Bullish
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
TipRanks News
Bullish
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX)
TipRanks News
Bullish
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
TipRanks News
Neutral
Gain announces presentations on Phase 1b clinical study of GT-02287
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
GANX
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.25 articles
News Sentiment
This Week59%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is GANX’s Media Buzz Sentiment?
1 articles about GANX were published this week. In an average week, 1.25 articles are published.
    What is GANX’s weekly average amount of articles?
    In an average week, 1.25 articles about GANX are published.
      What is GANX’s News Sentiment?
      59% of articles about GANX were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week